Drugs / H021
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06627556 | Sep 2024 → Feb 2025 overdue | ulcerative colitis | Jiangsu Carephar Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06627556 ↗ |
| Route | Oral | “H021 oral tablet.” NCT06627556 ↗ |